IDEC-CE9 data

IDPH (San Diego) reported Phase I/II results in 40 patients, in which 20 patients from all dose levels showed reduction in signs and symptoms of moderate to severe arthritis.

The agent combines human and macaque antibodies. No adverse effects occurred, nor did repeat administration cause loss of clinical activity. ...